This product has not been evaluated by SAHPRA. For information purposes only — not intended to diagnose, treat, cure or prevent any disease.
Mind & MoodResearch vialsleeprecoverystressneuropeptideresearch
DSIP
Nonapeptide investigated for sleep and stress
R 715
5mg vial
Modest sleep-efficiency gainsSchneider-Helmert: 16 chronic insomniacs on IV DSIP 25 nmol/kg over three nights showed statistically higher sleep efficiency and shorter sleep latency than placebo.
Investigated in withdrawal symptomsSmaller open-label work has reported symptom relief in opiate and alcohol withdrawal.
Crosses the blood-brain barrierReaches CNS targets after peripheral administration despite its peptide structure.
Short cycle, low-dose footprintResearch use limited to 1–4 weeks at sub-milligram doses, keeping exposure minimal.
DSIP is a nonapeptide isolated by Schoenenberger and Monnier in 1977 from the cerebral venous blood of rabbits in induced slow-wave sleep. The receptor target has never been definitively identified, and its endogenous role remains debated. It crosses the blood-brain barrier and has been investigated for sleep, stress response, and opioid/alcohol withdrawal symptoms.
More in Mind & Mood
You might also like
Mind & MoodR 585
30mg vial
Semax
Synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analogue of ACTH(4-10) developed in 1980s Moscow. On Russia's List of Vital and Essential Drugs, prescribed there for stroke recovery and cognitive complaints.
View details →
Mind & MoodR 585
30mg vial
Selank
Synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Moscow as a stabilised analogue of the immunomodulatory peptide tuftsin. Registered as an anxiolytic in Russia.
View details →
Regulatory
This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.